Intravenous Immunoglobulin Treatment on a Patient Presenting with Severe COVID-19 and Impending Respiratory Failure: A Case Report

Background: As of February 2022, COVID-19 virus pandemic still plagues the earth with cases mostly related to the emergence of new variant, Omicron. Even after 2 years since its discovery, no mainstay of therapy has been established for severe-critical COVID-19. Amongst the proposed options of therapy, IVIG remain a controversy with studies stating for and against being equally vocal. In this article, we report a case of severe COVID-19 patient presenting with bilateral pneumonia, impending respiratory failure, acute kidney injury, and high risk for arteriovenous thromboembolism administered with IVIG therapy for 3 days. Patient saw improvement in his clinical condition several days following the final dose. Based on the outcome and pre-existing literatures, IVIG is recommended to be taken as an early consideration for those presenting with severe-critical COVID-19, particularly with suspected cytokine storm marked by high inflammatory value.